Skip to content

This Study is Comparing Pain Outcomes After Urethral Bulking When Participants Are Randomized to Two Different Pain Medication Regimens.

Lidocaine Jelly +/- Lidocaine Periurethral Injection for Urethral Bulking Analgesia: A Single-Blind Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07889687
Enrollment
46
Registered
2026-10-22
Start date
2025-10-26
Completion date
2027-07-01
Last updated
2026-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

We are doing this study to find the best way to manage pain during a procedure called urethral bulking. This procedure treats urine leakage that happens with coughing, laughing, sneezing, or physical activity. It works by injecting a gel-like substance around the urethra (the tube that urine comes out of) to help it stay closed when it should. We use a numbing gel (called lidocaine jelly) inside the urethra to help with pain during the procedure. In this study, we will also be administering lidocaine (numbing medication) injected around the urethra or a saline placebo (medical grade saltwater) injection, which has no numbing effect. A placebo is something that looks like a real treatment but doesn't have any medical effect. Both the lidocaine and the saline would be injected around the urethra using a small needle, and we'll compare how well they work at reducing pain.

Interventions

Periurethral injection of lidocaine

DRUGGyldo

Glydo

DRUGSaline

Saline injection

Sponsors

Northwell Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Intervention model description

Single blind RCT

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* SUI based on +CST or UDS

Exclusion criteria

* contraindication to lidocaine, allergy to coaptite, pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Pain scoreImmediately after procedure0-100mm visual analog score

Secondary

MeasureTime frameDescription
UDI-62 weeks after procedureIncontinence scale
IIQ-72 weeks after procedureIncontinence scale
PGI-I2 weeks after procedureoverall improvement after procedure

Countries

United States

Contacts

CONTACTCarly Gridley Co-investigator, MD
cgridley@northwell.edu815-631-4840

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 23, 2026